小分子,大きな影響:腫瘍学における標的治療の20年

Philippe L Bedard¹, David M Hyman², Matthew S Davids³

¹Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, ON, Canada.

Lancet (London, England)

|March 31, 2020

まとめ

小分子阻害剤は抗がん性および進行がんの治療において重要な治療薬です将来の研究でこれらの薬の有効性やパーソナライズド・メディカル・アプローチを最適化できます

科学分野:

腫瘍学
薬理学について
分子生物学

背景:

小分子阻害剤は,分子標的の特定と細胞機能の理解における進歩により,がん治療における重要な治療クラスを表しています.
多標的および選択性キナーゼ阻害剤は,進行し,治療に抵抗するがんの管理に不可欠であり,初期段階および再発/転移性疾患の設定にますます承認されています.

研究の目的:

癌治療における小分子阻害剤の現状を振り返る
将来の研究を導くために,阻害剤開発から学んだことを議論する.
次世代の抑制剤と精密医療戦略の可能性を探求する

主な方法:

癌治療における小分子阻害剤に関する既存の文献のレビュー.
補助剤と第一線オプションを含む治療用途の分析
薬剤耐性を克服し,治療指標を最適化するための戦略の議論

主要な成果:

小分子阻害剤は,進行したがんや耐性がんに対して有効です.
これらの薬剤は,補助療法および第一線療法を含む様々な臨床環境で承認されています.
学んだ教訓は,治療指数最適化,抵抗を克服し,組み合わせた治療法を開発することを強調しています.

結論:

小分子阻害剤の開発は,がん治療を大幅に進歩させました.
将来の方向性は,新しい,難易度の高い標的をターゲットにし,予測モデルを使用することです.
ダイナミックな臨床試験と液体生検を含む精密医療のアプローチは将来の癌治療に大きな可能性を秘めています

さらに関連する動画

09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.0K

08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.5K

関連する概念動画

02:57

Targeted Cancer Therapies

8.6K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

8.6K

02:49

Cancer Therapies

9.7K

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

9.7K

02:50

Combination Therapies and Personalized Medicine

5.8K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

5.8K

01:26

Targets for Drug Action: Overview

9.8K

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

9.8K

01:15

Drugs that Stabilize Microtubules

2.5K

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

2.5K

02:56

Treatment Resistant Cancers

3.6K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...